A Randomized, Double-blind, Placebo-controlled Proof-of-concept Parallel Group Clinical Trial to Investigate the Efficacy, Safety and Tolerability of Weekly Subcutaneous Dosing of CK-0045 in Participants With Overweight/Obesity and Type 2 Diabetes
Latest Information Update: 05 Jun 2025
At a glance
- Drugs CK 0045 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Proof of concept; Therapeutic Use
- Sponsors Cytoki Pharma
Most Recent Events
- 31 May 2025 Planned End Date changed from 1 Oct 2025 to 1 Jan 2026.
- 31 May 2025 Planned primary completion date changed from 1 Aug 2025 to 1 Oct 2025.
- 11 Feb 2025 Planned End Date changed from 1 Sep 2025 to 1 Oct 2025.